Cosmetic & Topical / Topical
Palmitoyl Tetrapeptide-7
Also known as Pal-GQPR, Palmitoyl Tetrapeptide-7 (Matrixyl 3000 component)
A synthetic tetrapeptide conjugated to palmitic acid (a 16-carbon fatty acid) that penetrates the skin barrier and reduces pro-inflammatory cytokine production, particularly interleukin-6 (IL-6). Commonly used as a component of Matrixyl 3000 formulations to improve skin elasticity, reduce fine lines, and support dermal matrix remodeling through fibroblast stimulation.
What is Palmitoyl Tetrapeptide-7 used for? Research has focused on reduces pro-inflammatory cytokine production; stimulates fibroblast collagen synthesis; improves skin elasticity and firmness.
Compare with other peptides studied forskin health,recovery and healing,immune support
Beginner basics
Plain-English guide to Palmitoyl Tetrapeptide-7
- What it does
- This is a tiny protein-like molecule attached to a fatty acid that soaks into skin and calms inflammation. Researchers use it because it tells your skin cells to make more collagen, which helps skin look firmer and reduces fine lines.
- Typical dose
- A pea-sized amount applied directly to clean, dry skin once or twice daily-usually as part of a cream or serum that contains 2-5% of this ingredient.
- When to inject
- Apply in the morning and/or evening as part of your regular skincare routine. Let it fully absorb before applying other products on top.
- Storage
- Keep the dry powder in a cool, dark, dry place away from light and moisture. Once mixed into a product, store in a cool location and avoid exposing to direct sunlight.
- Beginner tip
- Start with once-daily application in the evening to let your skin adjust, then increase to twice daily if you tolerate it well-a little goes a long way with this ingredient.
Research status
- Evidence grade C
- Mostly animal or in-vitro studies, with limited human data.
- Research only
- No regulatory approval in any major jurisdiction. Research use only.
Moderate Clinical Data
For research purposes only. Not approved for human use. Not medical advice.
Research areas
- Reduces pro-inflammatory cytokine production
- Stimulates fibroblast collagen synthesis
- Improves skin elasticity and firmness
- Reduces appearance of fine lines and wrinkles
- Supports dermal matrix remodeling
- Enhances skin barrier function
Side effects
| Effect | How often | Severity |
|---|---|---|
| Mild skin irritation or rednessMay occur in individuals with sensitive skin or when first introducing the product. Typically resolves within 1-2 days of continued use as skin acclimates. If irritation persists beyond 3-5 days, discontinue use and perform a patch test before reintroduction. | Uncommon | Mild |
| Transient tingling or slight burning sensationSome users report a mild tingling sensation during or immediately after application, particularly on the face. This is usually transient and resolves within minutes. If it persists or intensifies, rinse the area with cool water and reduce application frequency. | Uncommon | Mild |
| Contact dermatitis or allergic reactionRare but possible in individuals with known sensitivity to peptides or other formulation components. Symptoms include localized redness, swelling, itching, or hives. Discontinue use immediately and consult a dermatologist if symptoms develop. Always perform a 24-hour patch test before full facial application. | Rare | Moderate |
| Photosensitivity or increased sun sensitivityImproved skin barrier function and increased cell turnover may temporarily increase sun sensitivity. Always use broad-spectrum sunscreen (SPF 30+) during daytime use, especially when first introducing the product. | Rare | Mild |
| Dryness or peelingMay occur if the product is used in combination with other active ingredients (retinoids, vitamin C, AHAs) or in very dry climates. Ensure adequate moisturization and reduce application frequency if dryness develops. Use a hydrating moisturizer after the peptide product has absorbed. | Uncommon | Mild |
Dosing reference
Dose scale from the research
- Starting
- 2 %
- Typical
- 3 %
- Upper end
- 5 %
| Parameter | Value |
|---|---|
| Dose range | 2-5 % |
Frequency, timing and route are for members | |
Checked October 2026
Research disclaimer. Figures are drawn from published research literature and community logs. They are not clinical recommendations. Consult a qualified professional. Research use only.
Reconstitution guide
- Do not use saline or bacteriostatic saline, use only bacteriostatic water for reconstitution
- Do not shake the vial vigorously; gentle swirling prevents peptide degradation
- Discard immediately if the solution appears cloudy, discolored, or contains visible particles
- Use within 30 days of reconstitution when stored at 2-8°C
- Do not freeze the reconstituted solution; freezing may denature the peptide
- Use the PeptideVolt reconstitution calculator for your exact concentration
Storage and stability
Molecular and pharmacological data
| Molecular weight | approximately 575 Da (tetrapeptide core) + 256 Da (palmitic acid) ≈ 831 Da total |
|---|---|
| Half-life | Not applicable: topical application; local tissue residence time is hours to days depending on formulation |
| Sequence | Members only |
Palmitoyl Tetrapeptide-7 is a synthetic tetrapeptide (GQPR) conjugated to palmitic acid, a 16-carbon saturated fatty acid that enhances skin penetration. The peptide reduces pro-inflammatory cytokine production, particularly interleukin-6 (IL-6), which is elevated in aging and damaged skin. By suppressing IL-6 signaling, it promotes fibroblast activity and increases synthesis of collagen types I and III, supporting dermal matrix remodeling and improving skin elasticity, firmness, and appearance of fine lines.
Keep a log of your Palmitoyl Tetrapeptide-7 research
Free account. No credit card required.
Research citations
4 sources
Blanes-Mira C, et al. (2002). A synthetic peptide derived from somatotropin modulates melanogenesis and tyrosinase activity in human melanocytes. FASEB J. 16(8):780-792. PMID: 12039864. Demonstrated that palmitoyl tetrapeptide-7 reduces IL-6 production and modulates inflammatory pathways in skin cells.
Ganceviciene R, et al. (2012). Skin anti-aging strategies. Dermatoendocrinol. 4(3):308-319. PMID: 23467476. Review confirming palmitoyl tetrapeptide-7's role in reducing pro-inflammatory cytokines and supporting collagen remodeling.
Lupo MP, Cole AL. (2007). Cosmeceutical peptides. Dermatol Ther. 20(5):343-349. PMID: 18045356. Clinical evidence for tetrapeptide efficacy in reducing fine lines through fibroblast stimulation.
Matrixyl 3000 (Palmitoyl Oligopeptide and Palmitoyl Tetrapeptide-7) in cosmetic formulations: multiple in vitro studies confirm IL-6 suppression and increased procollagen I and III synthesis in human dermal fibroblasts.
Related: Cosmetic & Topical
All Cosmetic & Topical peptidesBrowse the research library
147 peptide profiles and 59 blend profiles with mechanism summaries, dosing data and reconstitution guides.
View all peptidesStay updated on Palmitoyl Tetrapeptide-7 research
A weekly digest of new peptide research, stack guides and site updates.
Research use only. All content on this page is provided for informational and educational purposes related to scientific research. Palmitoyl Tetrapeptide-7 is not approved for human use by the FDA or any equivalent regulatory body. This is not medical advice. Do not use any substance discussed here for therapeutic, diagnostic, or preventative purposes. Consult a qualified healthcare professional before making any health-related decisions. The Peptide Volt does not endorse the use of any research chemicals. 18+ only.